Last reviewed · How we verify
Surfactants
Surfactants is a Small molecule drug developed by Prof. Dr. Dr. Ursula Mirastschijski. It is currently in Phase 1 development.
Surfactants are chemical compounds that decrease the surface tension or interfacial tension between two liquids, a liquid and a gas, or a liquid and a solid. They are typically small molecules that function as emulsifiers, enabling water and oil to mix, and can also form foam.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Surfactants |
|---|---|
| Sponsor | Prof. Dr. Dr. Ursula Mirastschijski |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pragmatic Evaluation of Respiratory Distress Syndrome Treatment in Africa (PHASE4)
- SHAPE Pilot Trial: Skin Health and Allergy Prevention Exposure (NA)
- Hydroxychloroquin (HCQ) in chILD of Genetic Defect (NA)
- A National Registry For Pulmonary Alveolar Proteinosis
- Vojta Reflex Versus Lung Squeezing Technique in Respiratory Distress Preterm Neonate (NA)
- Premedication for Less Invasive Surfactant Administration Study (PRELISA) (PHASE4)
- Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes (EARLY_PHASE1)
- Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Surfactants CI brief — competitive landscape report
- Surfactants updates RSS · CI watch RSS
- Prof. Dr. Dr. Ursula Mirastschijski portfolio CI
Frequently asked questions about Surfactants
What is Surfactants?
Who makes Surfactants?
What development phase is Surfactants in?
Related
- Manufacturer: Prof. Dr. Dr. Ursula Mirastschijski — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing